


WHAT IS CLAIMED IS:

1. A serotonin reuptake inhibitor comprising:
 - a first part, wherein the first part comprises a moiety with antidepressant properties and having an affinity for the serotonin reuptake transporter (SERT); and
 - a second part, wherein the second part comprises a moiety having an affinity to serotonin (5-HT) receptors, and wherein the second part is coupled to the first part.
2. The serotonin reuptake inhibitor of claim 1, wherein the 5-HT is 5-HT_{1A}, 5-HT_{2B}, 5-HT_{2C}, or 5-HT₃.
3. The serotonin reuptake inhibitor of claim 1, wherein the 5-HT is 5-HT_{2A}.
4. A serotonin reuptake inhibitor having the general formula:



wherein X is F or CF₃;


n is 0 or 1;

A is N or C; and

Ar is an aryl moiety; and salt thereof.


5. A serotonin reuptake inhibitor comprising a bi-functional organic molecule combining serotonin (5-HT) receptor antagonism and serotonin reuptake inhibition into one molecular entity.
6. The serotonin reuptake inhibitor of claim 5, wherein the 5-HT is 5-HT_{1A}, 5-HT_{2B}, 5-HT_{2C}, or 5-HT₃.
7. The serotonin reuptake inhibitor of claim 5, wherein the 5-HT is 5-HT_{2A}.

8. A serotonin reuptake inhibitor comprising a structural homologue of an antidepressant serotonin-selective reuptake inhibitor (SSRI) capable of inhibiting serotonin reuptake transporter (SERT) coupled to a piperazine or piperidine moiety being antagonistic to a serotonin (5-HT) receptor.
9. The serotonin reuptake inhibitor of claim 8, wherein the 5-HT is 5-HT_{1A}, 5-HT_{2B}, 5-HT_{2C}, or 5-HT₃.
10. The serotonin reuptake inhibitor of claim 8, wherein the 5-HT is 5-HT_{2A}.
11. A serotonin reuptake inhibitor having the general formula:




wherein X is F or CF₃; and
salt thereof.


12. A serotonin reuptake inhibitor having the general formula:




wherein X is F or CF₃;
wherein NR₁R₂ is:



























13. A serotonin reuptake inhibitor having the formula:



14. A serotonin reuptake inhibitor having the formula:







, or

15. A method for treating depression in a patient, comprising:
administering the serotonin reuptake inhibitor of claim 1.
16. A method for treating depression in a patient, comprising:
administering the serotonin reuptake inhibitor of claim 4.

17. A method for treating depression in a patient, comprising:
administering the serotonin reuptake inhibitor of claim 5.
18. A method for treating depression in a patient, comprising:
administering the serotonin reuptake inhibitor of claim 8.
19. A method for treating depression in a patient, comprising:
administering the serotonin reuptake inhibitor of claim 12.
20. A pharmaceutical formulation for the treatment of depression in a patient, comprising:
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 1.
21. A pharmaceutical formulation for the treatment of depression in a patient, comprising:
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 4.
22. A pharmaceutical formulation for the treatment of depression in a patient, comprising:
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 5.
23. A pharmaceutical formulation for the treatment of depression in a patient, comprising:
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 8.
24. A pharmaceutical formulation for the treatment of depression in a patient, comprising:
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 12.